COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

in Vitro Fertilization (IVF) Media Protein and Live Birth Rates (SSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00708383
Recruitment Status : Completed
First Posted : July 2, 2008
Last Update Posted : July 2, 2008
Information provided by:
Texas Health Resources

Brief Summary:
Human conception in vivo occurs in a complex milieu that includes proteins. It has been speculated that the addition of proteins more complex than human serum albumin to culture media may improve IVF outcomes. Whether the expense, labor and risk of adding additional human-derived protein to IVF media are warranted is a question unanswered. Patients, undergoing routine IVF or ICSI, will be assigned to one of two treatment groups in a randomized, prospective clinical trial . Embryos will be cultured in either media supplemented with human serum albumin (HSA) as a solitary protein supplement or in media supplemented with HSA + SSS from the 2-PN stage until the time of embryo transfer. Clinical endpoints monitored will be implantation rate, clinical pregnancy rate and live birth rate. It is expected that the supplementation of commercial embryo culture media containing HSA with the more complex protein source, SSS, will result in an overall increase in implantation, clinical pregnancy, and live birth rates. In the balance, protein enrichment of media may represent opportunities to simultaneously increase the live birth rate and reduce the incidence of multiple gestations.

Condition or disease Intervention/treatment Phase
Infertility Pregnancy Outcome, Live Birth In Vitro Fertilization Other: 10% SSS embryo culture medium protein supplementation Other: 0.5% HSA embryo culture medium protein supplementation Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 538 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Study of Human Serum Albumin and Serum Substitute Supplement as Protein Supplements for IVF Culture and the Effect on Live Birth Rates
Study Start Date : September 2001
Actual Primary Completion Date : November 2002
Actual Study Completion Date : November 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Altretamine

Arm Intervention/treatment
Experimental: 1
Embryo culture medium supplemented with 0.5% HSA and 10% SSS
Other: 10% SSS embryo culture medium protein supplementation
10% SSS in addition to the 0.5% HSA already in the culture medium.

Active Comparator: 2
Embryo culture medium supplemented with 0.5% HSA only
Other: 0.5% HSA embryo culture medium protein supplementation
0.5% HSA in the culture medium

Primary Outcome Measures :
  1. Live birth [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Implantation rate [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First IVF or any donor oocyte cycle
  • The eggs may be fertilized with conventional IVF methodology or by using intracytoplasmic sperm injection (ICSI).
  • When performing ICSI, ejaculated sperm must be used
  • 40 years of age or younger on the day of egg retrieval

Exclusion Criteria:

  • One or more previous failed IVF cycles
  • Use of epididymal or testicular sperm for ICSI
  • Older than 40 years of age

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00708383

Layout table for location information
United States, Texas
Presbyterian Hospital of Dallas
Dallas, Texas, United States, 75231
Presbyterian Hospital of Plano
Plano, Texas, United States, 75093
Sponsors and Collaborators
Texas Health Resources
Layout table for investigator information
Principal Investigator: Marius Meintjes, PhD Texas Health Resources

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Marius Meintjes, Presbyterian Hospital of Dallas Identifier: NCT00708383    
Other Study ID Numbers: PresbyterianHDallasARTS-SSS
First Posted: July 2, 2008    Key Record Dates
Last Update Posted: July 2, 2008
Last Verified: June 2008
Keywords provided by Texas Health Resources:
embryo development
embryo quality
IVF/ICSI outcome
multiple pregnancy
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female